(RVTY) Revvity - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 10.816m USD | Total Return: 5.3% in 12m
Avg Turnover: 122M
EPS Trend: -65.3%
Qual. Beats: 1
Rev. Trend: 48.5%
Qual. Beats: 2
Warnings
Choppy
Tailwinds
No distinct edge detected
Revvity, Inc. (RVTY), formerly known as PerkinElmer, provides specialized health science solutions across the life sciences and diagnostics sectors. The company develops and manufactures reagents, assay platforms, imaging technologies, and software used for genomic workflows, drug discovery, and clinical testing. Its diagnostic portfolio specifically targets early detection of genetic disorders, infectious diseases, and oncology markers.
Operating within the Life Sciences Tools & Services industry, Revvity utilizes a diversified business model that combines capital equipment sales with high-margin recurring revenue from consumables and service subscriptions. This sector is characterized by high barriers to entry due to stringent regulatory requirements and the technical complexity of next-generation sequencing and immunodiagnostics.
The company serves a global client base including pharmaceutical firms, academic institutions, and government health agencies under an extensive portfolio of established brand names. To better understand how these revenue streams impact long-term valuation, you may wish to examine the detailed financial metrics available on ValueRay. Headquartered in Waltham, Massachusetts, Revvity remains a key infrastructure provider for modern biotechnology research and clinical diagnostics.
- Biotechnology R&D spending levels dictate demand for drug discovery and genomic workflows
- Expansion of immunodiagnostics and newborn screening kits drives recurring high-margin reagent revenue
- China market recovery and geopolitical tensions influence long-term life sciences growth trajectory
- Strategic integration of BioLegend and Euroimmun acquisitions impacts overall operating margin profile
| Net Income: 241.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.12 > 1.0 |
| NWC/Revenue: 30.65% < 20% (prev 60.28%; Δ -29.63% < -1%) |
| CFO/TA 0.05 > 3% & CFO 571.4m > Net Income 241.0m |
| Net Debt (2.63b) to EBITDA (774.0m): 3.40 < 3 |
| Current Ratio: 1.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (111.9m) vs 12m ago -6.95% < -2% |
| Gross Margin: 51.44% > 18% (prev 0.54%; Δ 5.09k% > 0.5%) |
| Asset Turnover: 23.83% > 50% (prev 22.41%; Δ 1.42% > 0%) |
| Interest Coverage Ratio: 3.84 > 6 (EBITDA TTM 774.0m / Interest Expense TTM 93.9m) |
| A: 0.07 (Total Current Assets 2.13b - Total Current Liabilities 1.24b) / Total Assets 12.0b |
| B: 0.51 (Retained Earnings 6.09b / Total Assets 12.0b) |
| C: 0.03 (EBIT TTM 361.0m / Avg Total Assets 12.2b) |
| D: 1.26 (Book Value of Equity 6.09b / Total Liabilities 4.81b) |
| Altman-Z'' = 3.67 = AA |
| DSRI: 1.07 (Receivables 691.4m/617.4m, Revenue 2.90b/2.77b) |
| GMI: 1.06 (GM 51.44% / 54.35%) |
| AQI: 1.01 (AQ_t 0.77 / AQ_t-1 0.76) |
| SGI: 1.05 (Revenue 2.90b / 2.77b) |
| TATA: -0.03 (NI 241.0m - CFO 571.4m) / TA 12.0b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 96.83 with a total of 2,188,900 shares traded.
Over the past week, the price has changed by +1.41%,
over one month by +11.56%,
over three months by -2.13% and
over the past year by +5.29%.
Revvity has received a consensus analysts rating of 4.16. Therefore, it is recommended to buy RVTY.
- StrongBuy: 10
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 113.6 | 17.4% |
P/E Trailing = 46.6106
P/E Forward = 17.9533
P/S = 3.7265
P/B = 1.5058
P/EG = 0.5925
Revenue TTM = 2.90b USD
EBIT TTM = 361.0m USD
EBITDA TTM = 774.0m USD
Long Term Debt = 2.63b USD (from longTermDebt, last quarter)
Short Term Debt = 575.8m USD (from shortTermDebt, last quarter)
Debt = 3.49b USD (from shortLongTermDebtTotal, last quarter) + Leases 142.3m
Net Debt = 2.63b USD (calculated: Debt 3.49b - CCE 860.3m)
Enterprise Value = 13.4b USD (10.8b + Debt 3.49b - CCE 860.3m)
Interest Coverage Ratio = 3.84 (Ebit TTM 361.0m / Interest Expense TTM 93.9m)
EV/FCF = 27.23x (Enterprise Value 13.4b / FCF TTM 493.9m)
FCF Yield = 3.67% (FCF TTM 493.9m / Enterprise Value 13.4b)
FCF Margin = 17.02% (FCF TTM 493.9m / Revenue TTM 2.90b)
Net Margin = 8.30% (Net Income TTM 241.0m / Revenue TTM 2.90b)
Gross Margin = 51.44% ((Revenue TTM 2.90b - Cost of Revenue TTM 1.41b) / Revenue TTM)
Gross Margin QoQ = 54.51% (prev 43.80%)
Tobins Q-Ratio = 1.12 (Enterprise Value 13.4b / Total Assets 12.0b)
Interest Expense / Debt = 2.69% (Interest Expense 93.9m / Debt 3.49b)
Taxrate = 18.20% (9.10m / 50.0m)
NOPAT = 295.3m (EBIT 361.0m * (1 - 18.20%))
Current Ratio = 1.72 (Total Current Assets 2.13b / Total Current Liabilities 1.24b)
Debt / Equity = 0.49 (Debt 3.49b / totalStockholderEquity, last quarter 7.18b)
Debt / EBITDA = 3.40 (Net Debt 2.63b / EBITDA 774.0m)
Debt / FCF = 5.33 (Net Debt 2.63b / FCF TTM 493.9m)
Total Stockholder Equity = 7.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.98% (Net Income 241.0m / Total Assets 12.0b)
RoE = 3.28% (Net Income TTM 241.0m / Total Stockholder Equity 7.34b)
RoCE = 3.62% (EBIT 361.0m / Capital Employed (Equity 7.34b + L.T.Debt 2.63b))
RoIC = 2.61% (NOPAT 295.3m / Invested Capital 11.3b)
WACC = 8.19% (E(10.8b)/V(14.3b) * Re(10.12%) + D(3.49b)/V(14.3b) * Rd(2.69%) * (1-Tc(0.18)))
Discount Rate = 10.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.67 | Cagr: -4.27%
[DCF] Terminal Value 74.62% ; FCFF base≈506.0m ; Y1≈483.6m ; Y5≈464.0m
[DCF] Fair Price = 41.81 (EV 7.30b - Net Debt 2.63b = Equity 4.66b / Shares 111.6m; r=8.35% [WACC [floored]]; 5y FCF grow -5.76% → 2.50% )
EPS Correlation: -65.29 | EPS CAGR: -4.83% | SUE: 1.17 | # QB: 1
Revenue Correlation: 48.51 | Revenue CAGR: 1.14% | SUE: 2.06 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.22 | Chg30d=-5.44% | Revisions=-71% | Analysts=12
EPS next Quarter (2026-09-30): EPS=1.31 | Chg30d=-3.36% | Revisions=-57% | Analysts=12
EPS current Year (2026-12-31): EPS=5.24 | Chg30d=-2.98% | Revisions=-75% | GrowthEPS=+3.6% | GrowthRev=-0.4%
EPS next Year (2027-12-31): EPS=5.81 | Chg30d=-3.27% | Revisions=-75% | GrowthEPS=+10.9% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -75%